FINWIRES · TerminalLIVE
FINWIRES

Simcere Pharma Wins Promotion Rights for PrimeGenX's Atopic Dermatitis Drug

By

Simcere Pharmaceutical (HKG:2096) entered into an exclusive promotion service agreement with PrimeGenX Therapeutics for Pumecitinib Gel, a Monday Hong Kong bourse filing said.

Under the agreement, Simcere obtained exclusive promotion rights for the drug's dermatology indications in mainland China, Hong Kong, and Macau.

Pumecitinib Gel is described as the "world's first" JAK inhibitor gel for atopic dermatitis and is also being developed for additional dermatology indications, including atopic dermatitis in children aged 2 to 11, prurigo nodularis, and non-segmental vitiligo, according to the filing.

Related Articles

Asia

Lachlan Star Says Western Australia Gold Project Drilling Extends Mineralization, Shares Fall 3%

Lachlan Star (ASX:LSA) extended mineralization at the New Waverley gold project in Western Australia via a maiden 13-hole 1,031-meter diamond drilling program, according to a Tuesday Australian bourse filing.It encountered intercepts of 7.6 meters at 2.65 grams-per-tonne grade of gold from 18.5 meters, as well as 1.6 meters at 9.83 g/t grade of gold from 44.5 meters.A follow-up reverse circulation drilling program of around 2,400 meters will begin within the month, designed to infill and extend known mineralization.Its shares fell 3% in recent trading on Tuesday.

$ASX:LSA
Asia

Market Chatter: DBS Group to Establish Two New Wealth Centers in Singapore

DBS Group (SGX:D05) plans to establish two new wealth centers in Singapore by the end of 2027 to meet rising demand for its wealth management services, The Straits Times reported Monday.The wealth centers will complement the bank's existing DBS Treasures centers in the city-state.The centers are designed to offer services, including portfolio advisory to affluent and high-net-worth customers, the report said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

$SGX:D05
Asia

Vitrafy Life Sciences Partners With Vitalant Innovation Center on Red Blood Cell Preservation Technology

Vitrafy Life Sciences (ASX:VFY) has partnered with US healthcare organization Vitalant Innovation Center to address a "looming crisis" for red blood cell preservation, according to a Tuesday filing with the Australian bourse.The companies aim to configure Vitrafy's cryopreservation ecosystem as a successor to legacy technology and products that will be discontinued from 2027, which poses a threat to red blood cell stockpiles, per the filing.To support that objective, Vitrafy will initially place two cryopreservation freezing units at the Vitalant Innovation Center in Denver. The placement will not generate revenue, but the company expects the collaboration "to support broader market and government engagement toward a unified response," it said.

$ASX:VFY